The Week in Pharmaceuticals: Action, Reaction and Insight – Week Ending June 21, 20
By Barbara Obstoj-Cardwell. editor
Key research news from last week included US liver biotechnology company Mirum Pharmaceuticals reporting positive Phase IIb data for its cholangitis drug volixibat. British pharmaceutical giant AstraZeneca released disappointing data from Phase III trials for its breast cancer drug Truqap (capivasertib). Denmark’s Zealand Pharma also presented new data on its weight loss candidate petrelintide, an amylin agonist that could compete with current blockbuster obesity treatments. On the regulatory side, US company Sarepta Therapeutics received a welcome expanded approval from the US Food and Drug Administration (FDA) for its Duchenne muscular dystrophy drug Elevidys to cover older patient age groups.
Volixibat update offers promising VANTAGE upon approval
This article is available to registered users. To continue reading, please register for free. A free trial gives you one week’s access to exclusive features, interviews, summaries and commentary from the brightest minds in pharma and biotech. If you are already a registered user, please log in. If your trial has expired, you can log in here.
Log in to your account
Try before you buy
Free
7 days trial access
Free trial
- All the latest news that makes a difference in the pharmaceutical and biotech industry
- Exclusive features, podcasts, interviews, data analysis and commentary from our global network of life sciences reporters.
- Get the daily news newsletter “The Pharma Letter” free forever.
Become a subscriber
820 €
Or £77 per month
Subscribe now
- Unlimited access to industry-leading news, commentary and analysis from the pharmaceutical and biotechnology sectors.
- News on clinical trials, conferences, mergers and acquisitions, licensing, financing, regulatory, patents and legal, executive appointments, business strategy and financial results.
- Daily summary of the most important events in the pharmaceutical and biotechnology industry.
- Monthly detailed briefings on board appointments and M&A news.
- Choose between a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable service for the life sciences, providing a daily update on performance personnel and products. It is one of the most important pieces of information that keeps me informed
Chairman, Sanofi Aventis UK
Pepsi and Delta: Consumers are looking for added value
Film about a book that makes people “cry like babies” hits theaters this year
Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a class action lawsuit has been filed against Enphase Energy, Inc. in the U.S. District Court for the Northern District of California.
About The Author
